(Total Views: 657)
Posted On: 10/08/2022 11:31:29 AM
Post# of 148870
That is weird. It makes you wonder, if a safe immune system modulator might help?
Dr Gaylis:
"In an exploratory trial treating “long COVID” with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383814/
Dr Gaylis:
"In an exploratory trial treating “long COVID” with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383814/
(3)
(0)Scroll down for more posts ▼
